

## **Market Announcement**

3 June 2019

### LBT Innovations Limited (ASX: LBT) - Trading Halt

#### **Description**

The securities of LBT Innovations Limited ('LBT') will be placed in trading halt at the request of LBT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 5 June 2019 or when the announcement is released to the market.

#### **Issued by**

#### **Lauren Osbich**

Compliance Adviser, Listings Compliance (Sydney)



3 June 2019

**ASX** market Announcements

By email: tradinghaltssydney@asx.com.au

Dear Sir/Madam

# TRADING HALT REQUEST LBT INNOVATIONS LIMITED (ASX: LBT)

LBT Innovations Limited (**LBT**) requests a trading halt be placed on its securities immediately, pending an announcement to the market in relation to a capital raise.

LBT is not aware of any reason that a trading halt should not be placed on its securities.

The trading halt is expected to be lifted by no later than commencement of trading on 5 June 2019, pending release of an announcement by LBT in relation to the capital raising.

Yours sincerely,

Dan Hill

**Company Secretary** 

- ENDS -

#### **About LBT Innovations**

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

#### **CONTACTS**

LBT Innovations	Investor Enquiries
Brent Barnes	David Allen / John Granger
Chief Executive Officer & Managing Director	Hawkesbury Partners
Tel: +61 8 8227 1555	Tel: +61 2 9103 9494
E: info@lbtinnovations.com	E: dallen@hawkesburypartners.com